Introduction
Hashimoto's thyroiditis (HT) is the most common human organ-specific autoimmune disease. Although data on its global prevalence are limited, it is estimated to affect 1-2% of adult women in the US [1, 2] and is the most common cause of hypothyroidism in iodine-sufficient areas of the world. Moreover, HT is also often related to structural changes and nodules onset, so that the diagnosis and the treatment are relevant for patients' health. In this view, thyroid disease represents a constantly evolving chapter in clinical practice. So we explored the application of innovative techniques to deepen the assessment of neck disease [3, 4] and to improve the diagnostic accuracy by integrating conventional ultrasonography, qualitative color-doppler analysis, and both strain and shear wave elastography [5] .
Abstract
Purpose Autoimmune thyroiditis and its complications for the reproductive system are a growing problem. Selenium is a common ingredient in numerous food supplements recommended for thyroiditis and pregnancy. A fast, simple method to measure serum selenium concentration will improve knowledge of its pharmacokinetics and toxicity. Aim To validate a useful method to measure serum selenium concentration and to study selenium absorption and accumulation in a prospective interventional study of prolonged treatment. Methods Thirty healthy volunteers received a single dose of l-selenomethionine one tablet (83 mcg) (Phase 1), a single dose of two tablets (Phase 2), and two tablets daily for 14 days (Phase 3). Total selenium and selenium time profiles were generated by serial sampling (T0, T3, T6, T12, and T24 hours after ingestion-Phases 1 and 2; and T0 and T24 hours-Phase 3). Selenium concentration was investigated by open-vessel acid digestion of small serum volumes followed by hydride generation atomic fluorescence spectroscopy analysis.
Particularly, the diagnosis of hypothyroidism also presented some difficulties. For that reasons, data from literature established normal reference ranges for thyroid hormone between different age groups [6] . Moreover, increase in the annual frequency of autoimmune thyroid diseases has been observed over the last three decades [7] . Indeed, authors explored the pathways involved in HT, showing an association with a Th1-mediated inflammation with a decreased Th1-and Th17 cytokine secretion by CD4+ T cells, together with an enhanced tissue expression of CXCL10, not necessarily in the presence of increased circulating levels of CXCL10 [8] . So that the role of CXCL10 has become crucial in the study of inflammation and related target therapies for cardiovascular and metabolic diseases also [9] . Thyroid autoimmunity has been shown to be associated with multiple adverse outcomes in the reproductive system. There is growing literature evidence of an association between thyroid antibody positivity and negative pregnancy outcomes [10] . Pregnancy is a delicate stage of life during which the hormonal, immunological, and nutritional balance is very unstable. Adjustments in nutrient metabolism to maintain maternal homeostasis and to prepare the mother for breast-feeding are often needed, through use of supplements. Selenium is present in many of these supplements [11] .
Selenium is an essential trace element with an important role in immunity, defense against tissue damage, and thyroid function. Selenium deficiency has been associated with numerous conditions, including increased thyrocytes' damage, infections, and cancer [12] . Selenium supplementation has a promising effect on pregnancy outcomes, and ongoing studies and meta-analyses should soon enable proper recommendations to be proposed [13] . However, despite all of these beneficial properties, very little is known about its absorption, accumulation and toxicity, or the geographic distribution of selenium deficiency. It is also unclear what happens to selenium from its ingestion to its excretion from the body [14] .
The quantification of serum selenium concentration is problematic, due to its low concentrations and the complexity of the biological matrix. Although no reference method has yet been defined, the analysis usually involves closed-vessel microwave-assisted acid digestion of the serum sample followed by selenium determination by atomic absorbance spectroscopy coupled to hydride generation (HG-AAS) or by inductively coupled plasma mass spectrometry (ICP-MS) [15] [16] [17] [18] [19] .
The use of a microwave oven for pre-treatment ensures the sample's efficient mineralization and reduced loss of volatile species; however, it is time-consuming and requires relatively high sample volumes (about 1 mL) [20] .
HG-AAS is a well-established technique for the analysis of trace elements in biological matrices, but its sensitivity is impaired by the high background noise and the data quality is often influenced by matrix effects that must be carefully managed [20] ) interference and has a relatively low sensitivity, due to the low ionization efficiency of selenium [15] . A good analytical performance can therefore only be obtained with very expensive high-resolution instruments. Hydride generation atomic fluorescence spectroscopy (HG-AFS) is a convenient method for the determination of serum selenium concentration, as it enables highly sensitive and selective selenium analysis, even in complex matrices [18] .
These data highlight the limits of the methods available. To date, a validated method that facilitates and makes it reproducible and expendable to measure serum selenium concentration is lacking. HG-AAS can represent a valid alternative given its characteristics.
The aim of this study was to validate a rapid and reliable method for the quantification of serum selenium concentration by HG-AFS and to study the absorption and accumulation of selenium, in order to evaluate a prolonged treatment.
Methods

Study design
This was a prospective interventional study. The institutional review board of "Sapienza" University of Rome approved the protocol and all subjects gave their written informed consent. The STARD checklist flow diagram was used and the study was carried out in January 2015.
Participants
Patients were enrolled according to the following inclusion criteria: age 25-40 years. Exclusion criteria were: pregnancy, concomitant use of estrogen/progestin, proton pump inhibitors, anticoagulants or food supplements, gastrointestinal disease, known malabsorption disorders, and hypothyroidism.
Setting and methods
30 healthy volunteers were enrolled for three consecutive study phases. Phase 1: single dose of l-selenomethionine one tablet (83 mcg). Phase 2: after 7-day washout, the same volunteers received a single dose of l-selenomethionine two tablets (166 mcg). Phase 3: the same volunteers then received two tablets daily for 14 days (no washout). Total selenium and selenium time profiles were generated by sampling and analyzing serum at times T0, T3, T6, T12, and T24 hours after ingestion of one or two tablets (Phases 1 and 2) and at T0 and T24 hours after the last dose of two tablets (+15 days) for Phase 3. Selenium concentration was investigated by open-vessel acid digestion of small serum volumes (200 µL) followed by HG-AFS analysis.
Open-vessel acid digestion was performed in polypropylene tubes by adding 2 mL of HNO 3 (67%; Promochem, LGC Standards GmbH, Wesel, Germany) and 1 mL H 2 O 2 (30%; Promochem, LGC Standards GmbH, Wesel, Germany) to the serum sample; the solutions thus obtained were kept for 30 min at 80 °C in a water bath. After cooling, the solutions were diluted to 5 mL with ultrapure water. Selenium was determined by 8220 Titan HG-AFS (FullTech Instruments, Rome, Italy); 5% HCl (Promochem, LGC Standards GmbH, Wesel, Germany) was used as the carrier and 2% NaBH 4 (Sigma-Aldrich Chemie GmbH, St. Louis, USA) in 0.5% NaOH (Carlo Erba Reagenti Srl, Rodano, MI) as the reducing agent.
Statistical methods
Statistical analysis was performed with SPSS for Windows, version 21.0 (SPSS, Inc.). Continuous variables are reported as mean ± 1 SD. The descriptive analyses were performed considering all volunteers enrolled in the three phases of the study and percentage changes over baseline were calculated. Comparative analysis between timeline profiles vs. baseline was performed as appropriate by Student t test or two-way repeated-measure ANOVA. All statistical comparisons were performed with two-tailed significance tests, with p < 0.05 considered statistically significant. Area under the curve (AUC) was calculated as the integral of plasmatic concentration vs. time since dose (H), to analyze the pharmacokinetic parameter and selenium bioavailability (mcg/L x H).
Results
Thirty healthy volunteers (18 women, 12 men) were enrolled according to the inclusion and exclusion criteria and completed the study. The mean age was 30.87 ± 8.5 years. 3/30 subjects (10%) had Hashimoto's thyroiditis. 2/30 (6.6%) subjects were under LT4 treatment with a good euthyroid state. 5/30 (16.6%) subjects were smokers. There was a significant increase in serum selenium concentration in all treatment phases (see Table 1 ). In Phase 1 (single dose of one tablet), there was a significant increase at T3 (baseline: 76.5 ± 9.86 mcg/L vs. T3: 82.8 ± 13.13 mcg/L; ∆ = 9.96 ± 5.44%; p = 0.000). This was maintained at T6 (82.0 ± 11.10 mcg/L; p = 0. (Fig. 3) . The validation of HG-AFS included the measurement parameters and intensity fluorescence signal (IFS) setting for AFS, as reported in Table 2 .
A six-point matrix-matched external standard calibration was performed by diluting a standard solution (10,016 mg/L; SCP Science, Baie D'Urfé, Canada) in 15% HNO 3 to obtain solutions in the concentration range 0.5-10 µg/L.
The absence of significant matrix effects was confirmed by applying the standard addition method (selenium concentrations added to the acidic solution obtained from the open-vessel serum digestion ranging from 0.5 to 10 µg/L); the slopes of the two calibration lines (concentrations of external standard or of standard added to the real matrix vs. instrumental signal) were in agreement within a 3% deviation. Limits of detection (LODs) and of quantification (LOQs) were calculated, respectively, as three and ten times σ/b, where σ is the standard deviation (SD) of the blank determination (ten replicates) and b is the slope of the calibration curve. LODs and LOQs for the undiluted serum were 2 and 6 µg/L, respectively. The proposed digestion procedure was validated by comparing the results of open-vessel digestion with those obtained by microwave-assisted closed-vessel acid digestion (MAE). This was performed by following the procedure described in Harrington et al. [15] . Linear regression of the inter-comparison (supplementary material S1) was good (Pearson coefficient = 0.995), with a slope close to 1 (0.91) and an intercept close to 0 (0.14 µ/L). A further validation was performed by applying the two digestion procedures to the reference material ERM-DA 120a (LGC Limited, Teddington, Middlesex, UK). The obtained recovery (6 replicates) was 92 ± 5 and 96 ± 4%, Fig. 1 The graph represents the serum selenium concentration (mcg/L) over time in the Phase 1-single dose of l-selenomethionine one tablet (83 mcg), Phase 2-in which after 7 days washout the same volunteers received a single dose of l-selenomethionine two tablets (166 mcg), and Phase 3-in which the same volunteers consecutively to Phase 2 received two tablets daily for 14 days (no washout) Fig. 2 The graph represents the serum selenium concentration (percentage %) over time in the Phase 1-single dose of l-selenomethionine one tablet (83 mcg), Phase 2-in which after 7 days washout the same volunteers received a single dose of l-selenomethionine two tablets (166 mcg), and Phase 3-in which the same volunteers consecutively to Phase 2 received two tablets daily for 14 days (no washout) Fig. 3 The graph shows the AUC calculated for Phase 1-single dose of l-selenomethionine one tablet (83 mcg). Boxes represent selenium bioavailability time pattern corresponding to a ∆AUC at different timings: T0-T3, T0-T6, and T0-T12 respectively, [20] for the proposed open-vessel procedure and for MAE. Although, as expected, MAE showed a slightly better performance, the results were comparable (p = 0.13) and the open-vessel digestion proved to be a reliable, simple, and straightforward procedure that can be easily and economically transferred to routine application. The recovery percentage obtained from the reference material was used to correct all serum selenium concentration results.
Discussion
This study used a new, fast, and reliable approach to analyze the absorption and bioavailability of selenium. The use of HG-AFS to quantify selenium in serum offers an economical way to manage thyroid metabolism in various conditions for which l-selenomethionine supplementation is recommended, such as autoimmune thyroiditis and pregnancy.
The analytical methods used so far to analyze the metabolic products of the various selenium supplements in human body fluids were based mainly on HPLC combined with both elemental and molecular mass spectrometry [21] . These methods, however, had some limitations, mostly because of the analytical difficulties associated with the low serum selenium concentration, the complexity of the biological matrix, and the presence of large amounts of selenoproteins. Furthermore, the past analytical methods were expensive and time-consuming, also requiring high sample volumes of serum. On the contrary, HG-AFS represents an innovative and convenient method for the determination of serum selenium concentration, circumventing the analytical difficulties and enabling selenium analysis with high accuracy and sensitivity.
The incidence of autoimmune hyperthyroidism is about 99/100,000/year for Caucasian subjects, with a higher (85%) incidence in women than in men for all types of autoimmune thyroid disease. Most studies have investigated Caucasian populations in Scandinavia, Spain, the UK, and the USA [22] .
Selenium is available in several multivitamin/multi-mineral supplements and as a stand-alone supplement, often in the forms of selenomethionine or of selenium-enriched yeast (grown in a high-selenium medium), or as sodium selenite or sodium selenate [12] . The human body absorbs more than 90% of the selenium in selenomethionine but only about 50% from selenite. Selenium concentration is higher in the thyroid gland than in any other organ, and, like iodine, selenium has important functions in thyroid hormone synthesis and metabolism. The SU.VI.MAX study analyzed data from 1900 participants and demonstrated a relationship between selenium levels and thyroid gland function as well as an inverse relationship between serum selenium concentrations and thyroid volume, risk of goiter, and risk of thyroid tissue damage in people with mild iodine deficiency [23] . These results reached significance in women only. Rasmussen et al. analyzed 805 adults with mild iodine deficiency in Denmark, also finding a significant inverse association between serum selenium concentration and thyroid volume in women [17] . Randomized, controlled trials of selenium supplementation in patients with thyroid disease have produced varied results. A randomized, double-blind, placebo-controlled trial found no effect on thyroid function in elderly patients who received 100, 200, or 300 mcg/day of sodium selenite for 6 months and presented a significant increase in plasmatic selenium [24] . Similarly, a recent randomized, double-blind, placebo-controlled trial in 76 untreated euthyroid patients with Hashimoto's thyroiditis found that l-selenomethionine supplementation (166 mcg/day) for 6 months had a limited impact on the natural history of this disease, with levels of TSH, AbTPO, and CXCL10 unchanged [25] . Another randomized, double-blind, placebo-controlled trial compared the effects of 200 mcg/day sodium selenite to 1200 mg/day pentoxifylline (an anti-inflammatory agent) or placebo for 6 months in 159 patients with mild Graves' orbitopathy [26] . Compared with patients treated with placebo or pentoxifylline, those treated with selenium reported a higher quality of life. Furthermore, ophthalmic outcomes improved in 61% of patients in the selenium group compared with 36% of those in the placebo group, and only 7% of the selenium group had mild progression of the disease compared with 26% of those in the placebo group. The beneficial effects of selenium supplementation in patients with Graves' hyperthyroidism remain to be demonstrated.
In this regard, a recent study showed that the addition of selenomethionine to methimazole was not associated, in the short term, with a prompter control of hyperthyroidism compared to methimazole alone in a selenium-sufficient cohort of Graves' Disease patients, even if authors suggested that selenium might be beneficial in patients from selenium-deficient areas, as well as in the long-term outcome of antithyroid treatment [27] . Pregnant women with thyroid peroxidase antibodies tend to develop hypothyroxinemia, and thyroid dysfunction and hypothyroidism after giving birth [28] . The authors of a Cochrane review of hypothyroidism interventions during pregnancy concluded, based on a trial that administered supplements containing 200 mcg selenium as selenomethionine daily to 151 pregnant women with thyroid peroxidase antibodies [29] , that selenomethionine supplementation in this population is a promising strategy, especially for reducing postpartum thyroiditis [29] . However, the authors called for large randomized clinical trials to provide highquality evidence of this effect.
For this reason, we designed a multicenter, randomized, double-blind, placebo-controlled trial (Serena Study: NCT01465867) to establish the effects of selenomethionine supplementation in euthyroid pregnant women with autoimmune thyroiditis on antibody trend, thyroid function and structure, implantation rates, pregnancy rates, pregnancy outcome, and number of obstetrical, fetal, and neonatal complications. The study has now ended and the data are under analysis.
Although there are conflicting results in the literature regarding the effects of supplementation with selenium, such supplements are prescribed and administered during pregnancy and in patients with thyroid disease. Easier quantification of circulating selenium levels will enable greater use of assays to clarify baseline levels of circulating selenium and the patients who could benefit from taking selenium supplements. To this end, we developed and validated a new analytical procedure consisting of the openvessel acid digestion of small serum volumes (200 μL), with significantly reduced test time and sample handling, followed by HG-AFS analysis. The analytical performance of the method was evaluated with certified reference materials and inter-comparison of methods on field samples that found it to be reliable and easily applicable to routine analysis.
The baseline serum selenium concentration in our sample of healthy volunteers was in the lower part of the normal range [30] . Of note is that 16.6% of our subjects are smokers, a confounding factor for blood selenium quantification. In particular, cigarette smoking has been associated with lower selenium levels [31] . In our population, the number of smokers is too low to be able to express about significant differences, and we measured that basal serum selenium concentration of smokers was similar to no smokers. Furthermore, some authors hypothesize that smoking, promoting oxidative stress, may increase selenium utilization and cause depletion of tissue selenium stores [31] . This might suggest that smokers have a lower absorption of selenium, but in our study serum selenium concentration increased in all treatment phases in smokers, as well as in no smokers.
We included 3/30 subjects (10%) with HT and 2/30 (6.6%) subjects were under LT4 treatment. All the subjects had a good euthyroid state. Low selenium intake has been associated with increased risk of HT. As previously said, several studies have investigated the effects of organic and inorganic selenium compounds on the autoimmune markers of patients with HT. Therefore, it is possible that subjects with low serum selenium concentration and HT could take more benefit from SeMet supplementation. However, especially in presence of a good euthyroid state, HT should not alter the processes of absorption and accumulation of selenium. Anyway, despite the small number of subjects with HT, no differences in basal selenium serum concentration and in SeMet absorption and accumulation were seen compared to subjects without HT.
The baseline levels of our sample were lower than those reported for healthy European subjects in other studies [32, 33] . We found that a single tablet of l-selenomethionine produced an approximately 10% increase in selenium levels after 3 h and 7% after 12 h for an overall bioavailability of 32 ± 20 mcg/L x H, demonstrated by the AUC at T0-12 h. Doubling the dose seemed to slow absorption, with a statistically significant increase achieved only after 6 h, reaching a peak of concentration 16% increased from baseline that was higher than those obteined with a single tablet. The accumulation resulting from the consumption of the double dose was also maintained for 24 h, in contrast with the decay observed from 12 h onwards after taking a single tablet. Thanks to this rapid and reliable method of selenium dosage, we can observe that the results shown about selenium absorption suggest that the dosage of l-selenomethionine 166 mcg warranted a prolonged achievement of increased selenium blood levels.
Data demonstrated that prolonged administration of double dose of L-seleniomethionine produced a substantial selenium increase of 32% from baseline that is measurable at 24 h after withdrawal. Given the starting values of our subjects that were in the lower part of the normal range, the value achieved after the Phase 3 was compatible with an "optimum" circulating selenium concentration. The study therefore demonstrates that the bioavailability and accumulation of selenomethionine are assured by prolonged treatment with a double dose of supplement, and that the method used can be implemented easily, quickly. and economically in clinical practice. The use of HG-AFS is an efficient way to obtain preliminary information on circulating blood selenium concentrations and the absorption of various selenium supplements. Furthermore, the introduction of a fast, economic screening method would also enable investigation of the geographic distribution of selenium deficiency in western and other populations.
